OBJECTIVES: Here we report the results of a study in which natural estrogens were given transdermally cyclically and continuously for 1 year, and a progestin of the latest generation, namely nomegestrol acetate, was given for 10 days every month and for 15 days every 2 months. METHODS: The patients were a group of 34 post-menopausal women (51-56 years), 18 of whom (group A) were treated with continuous transdermal estradiol (50 micrograms/day) and cyclic oral nomegestrol at a dose of 5 mg/day for 15 days every 2 months for 1 year. The other 16 women (group B) were treated with cyclic transdermal estradiol for 3 weeks with oral nomegestrol for 10 days (12-21)/month. Endometrial thickness was evaluated by transvaginal ultrasonography befor...
OBJECTIVES: to compare the endometrial effects and uterine bleeding patterns associated with treatme...
Objective: To evaluate the safety and endometrial protection of low-dose transdermal estradiol (E2)/...
OBJECTIVES: To review the main findings of the Euralox 1 study - a multicentre, randomised, double-b...
OBJECTIVES: Here we report the results of a study in which natural estrogens were given transdermal...
OBJECTIVE: To compare the effects on endometrium, climacteric symptoms and the menstrual cycle, and ...
Objective: To establish the optimum oral daily dose of micronized medroxyprogesterone acetate, given...
OBJECTIVE: To evaluate the safety and endometrial protection of low-dose transdermal estradiol (E2...
Objective: To investigate the difference in histopathology and cell cycle kinetics in the menopausal...
OBJECTIVES: The oral combined formulation of levonorgestrel with estradiol valerate (LNG+EV) has de...
Objectives: To study: (1) factors influencing the prevalence and severity of climacteric symptoms a...
Objective: The objective of the present document was to review/summarize reported outcomes compared ...
OBJECTIVE: This progestin hormone replace-ment therapy (HRT) regimen in which estrogen is given cont...
Tibolone may be a safe hormonal treatment for postmenopausal women with residual endometriosis. STU...
OBJECTIVE: New regimens and routes of administration of hormonal replacement therapy (HRT) in clima...
The purpose of our study was to compare the effects of cyclical versus continuous transdermal oestro...
OBJECTIVES: to compare the endometrial effects and uterine bleeding patterns associated with treatme...
Objective: To evaluate the safety and endometrial protection of low-dose transdermal estradiol (E2)/...
OBJECTIVES: To review the main findings of the Euralox 1 study - a multicentre, randomised, double-b...
OBJECTIVES: Here we report the results of a study in which natural estrogens were given transdermal...
OBJECTIVE: To compare the effects on endometrium, climacteric symptoms and the menstrual cycle, and ...
Objective: To establish the optimum oral daily dose of micronized medroxyprogesterone acetate, given...
OBJECTIVE: To evaluate the safety and endometrial protection of low-dose transdermal estradiol (E2...
Objective: To investigate the difference in histopathology and cell cycle kinetics in the menopausal...
OBJECTIVES: The oral combined formulation of levonorgestrel with estradiol valerate (LNG+EV) has de...
Objectives: To study: (1) factors influencing the prevalence and severity of climacteric symptoms a...
Objective: The objective of the present document was to review/summarize reported outcomes compared ...
OBJECTIVE: This progestin hormone replace-ment therapy (HRT) regimen in which estrogen is given cont...
Tibolone may be a safe hormonal treatment for postmenopausal women with residual endometriosis. STU...
OBJECTIVE: New regimens and routes of administration of hormonal replacement therapy (HRT) in clima...
The purpose of our study was to compare the effects of cyclical versus continuous transdermal oestro...
OBJECTIVES: to compare the endometrial effects and uterine bleeding patterns associated with treatme...
Objective: To evaluate the safety and endometrial protection of low-dose transdermal estradiol (E2)/...
OBJECTIVES: To review the main findings of the Euralox 1 study - a multicentre, randomised, double-b...